We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Losartan (Cozaar) — angiotensin-receptor blocker (ARB)
An angiotensin-receptor blocker (Cozaar) — a first-line blood-pressure drug with proven human stroke-prevention and diabetic-kidney-protection outcomes. Its longevity/geroscience interest is the renin-angiotensin–aging axis plus a striking ANIMAL story: blocking the AT1 receptor dampens TGF-β signaling and restores muscle repair in aged/sarcopenic mice. But the anti-sarcopenia and lifespan benefits remain animal-only — not demonstrated in humans. A prescription drug used off-label, not a supplement.
Prescription medication — not a dietary supplement
Losartan is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Losartan doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 1995–2026.
Based on 612 studies · 18 meta-analyses · 582 RCTs
Confidence
High confidenceBy outcome
Losartan has strong human outcome evidence as an antihypertensive — LIFE showed stroke reduction beyond atenolol and RENAAL showed diabetic-kidney protection — and an unusually concrete muscle-aging mechanism (AT1/TGF-β blockade restores muscle repair and protects against disuse atrophy in aged mice). But the anti-sarcopenia and longevity benefits are animal-only, no human trial shows it extends lifespan or prevents sarcopenia, and its own Marfan trial (losartan ≈ atenolol on aortic-root growth) shows mechanism doesn't guarantee outcome — so the geroprotector use stays emerging.
593 randomised trials
80% were about Losartan in an audit of 50 of them
Every randomised or controlled trial of Losartan indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
51 trials ongoing or recruiting · 273 completed on ClinicalTrials.gov
82 of the completed trials have posted results
Registered trials show research momentum for Losartan, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Losartan is the prototype angiotensin-receptor blocker (ARB) — it blocks the angiotensin II type-1 (AT1) receptor rather than inhibiting ACE, giving the renin-angiotensin (RAS) benefits of an ACE inhibitor without the bradykinin-mediated cough.
It is a first-line antihypertensive with deep, robust human outcome data: the landmark LIFE trial showed losartan reduced cardiovascular events — driven by a significant reduction in stroke — more than the beta-blocker atenolol at equal blood-pressure lowering, and the RENAAL trial showed it slowed progression of diabetic kidney disease to end-stage renal failure.
Those are the proven human benefits: blood pressure, stroke prevention, and renal protection. Its place in a longevity collection rests on two threads.
First, the RAS is a conserved aging axis (the same rationale as the ACE inhibitor captopril) — angiotensin II signaling drives inflammation, oxidative stress, fibrosis, and cellular senescence, and RAS modulation is repeatedly framed as a candidate geroprotective pathway.
Second, and more specifically, losartan has a striking muscle-aging story in animals: AT1-receptor blockade attenuates excess TGF-β signaling, and in mice this normalizes muscle regeneration in Marfan and Duchenne models (Cohn 2007) and restores muscle remodeling while protecting against disuse atrophy in sarcopenic aged mice (Burks 2011, via both TGF-β blockade and IGF-1/Akt/mTOR activation).
The honest distinction this collection insists on: those anti-sarcopenia and muscle-regeneration findings are animal-only, and there is no human trial showing losartan extends lifespan, prevents sarcopenia, or improves muscle function in older adults — the muscle-aging case is mechanistic and preclinical.
The best counter-evidence within the drug's own literature reinforces the limits of extrapolating from mechanism: in the pivotal pediatric Marfan trial (Lacro 2014), losartan did NOT slow aortic-root dilation more than atenolol despite the compelling TGF-β rationale — a reminder that a clean mechanism does not guarantee a clinical outcome.
Losartan is generally well tolerated (better than ACE inhibitors on cough); class effects are dizziness/hypotension, hyperkalemia, and a contraindication in pregnancy. It is a prescription drug used off-label for its proposed geroprotective/muscle-aging effects; it is not a dietary supplement.
The score reflects strong human cardiovascular/renal outcomes plus an unusually concrete (but animal-only) muscle-aging mechanism, against unproven human longevity or anti-sarcopenia benefit.
Losartan blocks the angiotensin II type-1 (AT1) receptor, lowering angiotensin II signaling — the renin-angiotensin axis that, beyond blood pressure, drives inflammation, oxidative stress, fibrosis, and senescence.
AT1 signaling amplifies TGF-β; blocking it dampens canonical (Smad2/3) and noncanonical TGF-β signaling, restoring satellite-cell function and muscle regeneration — shown in myopathic and aged-mouse muscle.
In aged mice, losartan protected against disuse atrophy partly by increasing IGF-1/Akt/mTOR signaling — a muscle-homeostasis pathway distinct from its TGF-β effect (Burks 2011).
How Losartan works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Contraindicated — ARBs cause fetal renal and developmental harm.
Monitor kidney function and potassium closely.
Caution — first-dose hypotension; correct dehydration first and start low.
Additive hyperkalemia risk — can be dangerous.
Reduce ARB effect and can worsen renal function (the 'triple whammy' with diuretics).
ARBs raise lithium levels and toxicity risk.
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment.
Tip: Monitor potassium; avoid potassium supplements/salt substitutes, especially in renal impairment.
Tip: Much rarer than with ACE inhibitors; stop immediately and seek care.
Losartan has an evidence score of 4.2/10 — emerging evidence based on 612 indexed studies. An angiotensin-receptor blocker (Cozaar) — a first-line blood-pressure drug with proven human stroke-prevention and diabetic-kidney-protection outcomes. Its longevity/geroscience interest is the renin-angiotensin–aging axis plus a striking ANIMAL story: blocking the AT1 receptor dampens TGF-β signaling and restores muscle repair in aged/sarcopenic mice. But the anti-sarcopenia and lifespan benefits remain animal-only — not demonstrated in humans. A prescription drug used off-label, not a supplement. Representative study: PMID 11937178.
Dosing for Losartan: Off-label longevity/muscle-aging use mirrors low antihypertensive dosing (25–100 mg once daily) under a clinician. Not an approved longevity or anti-sarcopenia regimen; blood pressure, kidney function, and potassium should be monitored. Individual needs vary, so check the right dose for you with a healthcare provider.
Timing is flexible for Losartan — consistent daily use matters more than the time of day. Once daily (sometimes split), with or without food.
Losartan should be used with caution — talk to a healthcare provider before taking it. Reported side effects include angioedema, hyperkalemia, dizziness / hypotension. How often they occur is not established for all of them. Use caution if any of these apply to you: Pregnancy (fetal harm); Bilateral renal artery stenosis; Hyperkalemia.
CoQ10
Likely helpsA lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.
Red Yeast Rice
Likely helpsFermented rice containing natural statins that effectively lower LDL cholesterol — the original statin.
Berberine
Likely helpsActivates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism. Its only head-to-head trial with metformin cited here was a 36-person pilot, which does not show it can replace metformin.
Plant Sterols & Stanols
Too few graded studiesPlant sterols and stanols taken at about 2 to 3 g a day, usually in fortified foods or as capsules, lower LDL cholesterol by roughly 6 to 12% in more than a hundred randomised trials. No trial has tested whether they prevent heart attacks or strokes.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 614 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research